Drug Profile
Avoplacel - Pluri
Alternative Names: Placenta-derived cell therapy - Pluri; PLX-R-18; PLX-RADLatest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Hadassah Medical School; Pluristem Therapeutics
- Developer Case Western Reserve University; Fukushima Medical University; Hadassah Medical School; National Institute of Allergy and Infectious Diseases; Pluri; United States Department of Defense
- Class Stem cell therapies
- Mechanism of Action Bone marrow cell stimulants; Cell differentiation modulators; Cell replacements; Stem cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute radiation syndrome
- Phase I Graft-versus-host disease
- No development reported Aplastic anaemia; Chemical burns
Most Recent Events
- 08 Apr 2024 Pluri has patent protection for System and Methods for Immune Cells Expansion and Activation in Large Scale in the US
- 11 Jul 2023 Pharmacodynamics data from a phase II trial in Acute radiation syndrome released by Pluri
- 06 Jan 2023 Avoplacel is still in phase-I development in Graft-versus-host-disease (In the elderly, In adults) in Israel (IM, Injection) (Pluristem Therapeutics pipeline, January 2023)